11th IAS Conference on HIV Science (IAS 2021), Berlin, Germany, 18-21 July 2021

第 11 届 IAS HIV 科学会议 (IAS 2021),德国柏林,2021 年 7 月 18-21 日

基本信息

  • 批准号:
    10254560
  • 负责人:
  • 金额:
    $ 75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-06-09 至 2022-05-31
  • 项目状态:
    已结题

项目摘要

Project Summary The scientific and public health response against HIV/AIDS in the past four decades has been remarkable and unprecedented. Yet HIV transmission continues in many populations at unacceptably high rates despite testing and treatment availability, largely driven by stigma and discrimination and other social and structural determinants. IAS 2021 will be the key global scientific convening to review progress against remaining challenges in controlling the epidemic. Significant new insights that are expected to be shared at IAS 2021 include basic work on virology, immunology and HIV pathogenesis with a continued focus on the functional cure/remission agenda. Clinical research in HIV is entering a new era of longer acting and injectable formulations which will be highlighted at IAS 2021, along with the remaining challenges of adherence, pill fatigue, and multi-drug resistant variants. Pediatric clinical care issues will be a further key topic where the advances in newer integrase inhibitor-based regimens for infants and children will be a primary focus. In the prevention field, the finding of superiority for long-acting injectable cabotegravir as PrEP marks the beginning of a new era, with further evidence expected in this regard at IAS 2021, along with early data on the co-formulations of long-acting injectables with other products for contraception, opioid dependence, and other health conditions. In the implementation science field innovative testing, prevention, treatment, and surveillance modalities will feature prominently at IAS 2021. Finally, the COVID-19 pandemic is expected to be among the defining themes across all scientific tracks against the background of treatment interruptions worldwide and the many remaining uncertainties regarding HIV/SARS- CoV-2 interactions. While the IAS is making parallel provisions for shifting to a fully virtual delivery format if mandated by the state of the COVID-19 pandemic, IAS 2021 is planned to take place in Berlin from 18-21 July 2021, with a strong virtual presence to ensure broad access (expected attendance of 6,000 delegates). It will provide a critical platform for HIV science to re-convene in a country now characterized by a celebration of diversity and zero discrimination. Berlin is at the heart of Europe, with close connectivity to the most HIV-affected region in Europe—Central and Eastern Europe, in particular Ukraine, and the Russian Federation, where, in marked contrast to Germany, rights-based approaches to HIV programming are constantly challenged. Specific aims of IAS 2021 are to: 1. Accelerate basic science and clinical innovation for the development and application of person-centered, precision medicine for HIV, including pathogenesis, transmission, vaccines, remission and a functional cure. 2. Advance inter-disciplinary collaboration in clinical research to improve integrated care across all life stages and accelerate updates to treatment guidance especially for low and middle-income countries, infected children, persons with HIV, TB, viral hepatitis and COVID-19 infection; 3. Strengthen HIV prevention research to improve biomedical, behavioral and structural interventions and the integration of new tools, including long-acting injectable prevention technologies in prevention programs for those in need; 4. Advance core components of the implementation science agenda across the HIV prevention-to-care cascade in the COVID-19 era, including aspects of integration and approaches for meaningful community engagement and resourcing health systems; 5. Address HIV vulnerability and determinants of disease progression among key and marginalized populations, including novel interventions and implementation science to reduce stigma and discrimination, including intersectional stigmas of HIV, other diseases, homophobia, transphobia, and ethnic and racial disparities. The scientific program will consist of four tracks: Track A – Basic Science; Track B – Clinical Science; Track C – Prevention Science; and Track D – Social, Behavioral, and Implementation Science. Cross-cutting aspects will be covered in plenary talks that also connect the scientific tracks with community and leadership perspectives, and bridging sessions will cut across at least two of the tracks to provide opportunities for multi-disciplinary dialogues. The participation of young researchers, basic scientists and researchers in related fields such as non- communicable diseases will be strengthened by active solicitation of relevant science and the provision of specific financial support, in addition to increased remote-access options.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christopher C. Beyrer其他文献

Christopher C. Beyrer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Christopher C. Beyrer', 18)}}的其他基金

IAS 2023, the 12th IAS Conference on HIV Science, Brisbane, Australia, and virtually, 23-26 July 2023
IAS 2023,第 12 届 IAS HIV 科学会议,澳大利亚布里斯班,虚拟会议,2023 年 7 月 23-26 日
  • 批准号:
    10696505
  • 财政年份:
    2023
  • 资助金额:
    $ 75万
  • 项目类别:
HIVR4P 2023, the 5th HIV Research for Prevention Conference, Lima, Peru, and virtually, 22-26 October 2023
HIVR4P 2023,第五届艾滋病毒预防研究会议,秘鲁利马,虚拟会议,2023 年 10 月 22-26 日
  • 批准号:
    10617933
  • 财政年份:
    2023
  • 资助金额:
    $ 75万
  • 项目类别:
The 24th International AIDS Conference (AIDS 2022), 29 July-2 August 2022, Montreal, Canada and virtually
第 24 届国际艾滋病大会 (AIDS 2022),2022 年 7 月 29 日至 8 月 2 日,加拿大蒙特利尔
  • 批准号:
    10481133
  • 财政年份:
    2022
  • 资助金额:
    $ 75万
  • 项目类别:
HIV Research for Prevention Conference, HIVR4P 2020
HIV 预防研究会议,HIVR4P 2020
  • 批准号:
    9925854
  • 财政年份:
    2020
  • 资助金额:
    $ 75万
  • 项目类别:
Developmental Core
发展核心
  • 批准号:
    10384036
  • 财政年份:
    2020
  • 资助金额:
    $ 75万
  • 项目类别:
23rd International AIDS Conference (AIDS 2020), San Francisco and Oakland, United States, 6-10 July 2020
第 23 届国际艾滋病大会 (AIDS 2020),美国旧金山和奥克兰,2020 年 7 月 6-10 日
  • 批准号:
    10004757
  • 财政年份:
    2020
  • 资助金额:
    $ 75万
  • 项目类别:
Effectiveness of combination HIV preventive interventions for young Thai MSM
泰国年轻男男性接触者联合艾滋病毒预防干预措施的有效性
  • 批准号:
    10084364
  • 财政年份:
    2015
  • 资助金额:
    $ 75万
  • 项目类别:
Effectiveness of combination HIV preventive interventions for young Thai MSM
泰国年轻男男性接触者联合艾滋病毒预防干预措施的有效性
  • 批准号:
    9300829
  • 财政年份:
    2015
  • 资助金额:
    $ 75万
  • 项目类别:
Johns Hopkins HIV Epidemiology and Prevention Sciences Training Program
约翰·霍普金斯大学艾滋病流行病学和预防科学培训计划
  • 批准号:
    9897479
  • 财政年份:
    2013
  • 资助金额:
    $ 75万
  • 项目类别:
Johns Hopkins HIV Epidemiology and Prevention Sciences Training Program
约翰·霍普金斯大学艾滋病流行病学和预防科学培训计划
  • 批准号:
    8879021
  • 财政年份:
    2013
  • 资助金额:
    $ 75万
  • 项目类别:

相似海外基金

HIV/AIDS prevention and intervention: HIV surveillance methods, Per-exposure prophylaxis eligibility and HIV/STI testing behaviours among a cohort of people living with HIV.
HIV/艾滋病预防和干预:HIV 感染者群体中的 HIV 监测方法、每次暴露预防资格和 HIV/STI 检测行为。
  • 批准号:
    495195
  • 财政年份:
    2023
  • 资助金额:
    $ 75万
  • 项目类别:
International Traineeships in AIDS Prevention Studies (ITAPS)
艾滋病预防研究国际培训(ITAPS)
  • 批准号:
    10013921
  • 财政年份:
    2020
  • 资助金额:
    $ 75万
  • 项目类别:
International Traineeships in AIDS Prevention Studies (ITAPS)
艾滋病预防研究国际培训(ITAPS)
  • 批准号:
    10181081
  • 财政年份:
    2020
  • 资助金额:
    $ 75万
  • 项目类别:
UCLA AIDS Prevention and Treatment Clinical Trials Unit
加州大学洛杉矶分校艾滋病预防和治疗临床试验单位
  • 批准号:
    10166309
  • 财政年份:
    2020
  • 资助金额:
    $ 75万
  • 项目类别:
International Traineeships in AIDS Prevention Studies (ITAPS)
艾滋病预防研究国际培训(ITAPS)
  • 批准号:
    10597008
  • 财政年份:
    2020
  • 资助金额:
    $ 75万
  • 项目类别:
International Traineeships in AIDS Prevention Studies (ITAPS)
艾滋病预防研究国际培训(ITAPS)
  • 批准号:
    10386931
  • 财政年份:
    2020
  • 资助金额:
    $ 75万
  • 项目类别:
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment, and Care among Adolescents Living with HIV in Botswana
减少耻辱感,改善博茨瓦纳艾滋病毒感染青少年的艾滋病毒/艾滋病预防、治疗和护理
  • 批准号:
    9921510
  • 财政年份:
    2019
  • 资助金额:
    $ 75万
  • 项目类别:
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment, and Care among Adolescents Living with HIV in Botswana
减少耻辱感,改善博茨瓦纳艾滋病毒感染青少年的艾滋病毒/艾滋病预防、治疗和护理
  • 批准号:
    9753631
  • 财政年份:
    2019
  • 资助金额:
    $ 75万
  • 项目类别:
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment, and Care among Adolescents Living with HIV in Botswana
减少耻辱感,改善博茨瓦纳艾滋病毒感染青少年的艾滋病毒/艾滋病预防、治疗和护理
  • 批准号:
    10265667
  • 财政年份:
    2019
  • 资助金额:
    $ 75万
  • 项目类别:
Closing the Gap: Involving Indigenous Elders and youth in HIV/AIDS prevention using participatory filmmaking
缩小差距:利用参与式电影制作让土著老年人和青年参与艾滋病毒/艾滋病预防工作
  • 批准号:
    364681
  • 财政年份:
    2017
  • 资助金额:
    $ 75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了